A randomized trial of AmBisome monotherapy and combination of AmBisome and miltefosine for the treatment of VL in HIV positive patients in Ethiopia followed by secondary VL prophylactic treatment with pentamidine

Hdl Handle:
http://hdl.handle.net/10144/619245
Title:
A randomized trial of AmBisome monotherapy and combination of AmBisome and miltefosine for the treatment of VL in HIV positive patients in Ethiopia followed by secondary VL prophylactic treatment with pentamidine
Authors:
Hailu, Asrat; Diro, Ermias; Kolja, Stille; Ritmeijer, Koert; Yifru, Sisay; Griensven, Johan van; Zijstra, Ed; Dorlo, Thomas; Strub-Wougaft, Nathalie; Bardonneau, Clelia; Ellis, Sally; Alexander, Neal; Edwards, Tansy
Abstract:
General Objectives The overall objective of this trial is to identify a safe and effective treatment for VL in HIV coinfected patients. Primary Objective: To evaluate at day 29 assessment the efficacy of a combination regimen of AmBisome® + miltefosine and AmBisome® monotherapy in Ethiopian co-infected HIV + VL patients. Secondary Objectives: 1. To evaluate relapse-free survival at day 390 (after initial cure at day 29 or cure at day 58 after extended treatment). 2. To assess safety of the regimens. Other objectives: 1.To evaluate of viral load and CD4 count in all patients 2. To evaluate the pharmacokinetics of ARV, Ambisome and miltefosine and immune function markers in a subset of patients
Affiliation:
MSF-OCA
Issue Date:
Jul-2018
URI:
http://hdl.handle.net/10144/619245
Type:
Other
Language:
en
Description:
Research Protocol
Appears in Collections:
MSF Research Protocols

Full metadata record

DC FieldValue Language
dc.contributor.authorHailu, Asraten
dc.contributor.authorDiro, Ermiasen
dc.contributor.authorKolja, Stilleen
dc.contributor.authorRitmeijer, Koerten
dc.contributor.authorYifru, Sisayen
dc.contributor.authorGriensven, Johan vanen
dc.contributor.authorZijstra, Eden
dc.contributor.authorDorlo, Thomasen
dc.contributor.authorStrub-Wougaft, Nathalieen
dc.contributor.authorBardonneau, Cleliaen
dc.contributor.authorEllis, Sallyen
dc.contributor.authorAlexander, Nealen
dc.contributor.authorEdwards, Tansyen
dc.date.accessioned2018-07-31T13:29:18Z-
dc.date.available2018-07-31T13:29:18Z-
dc.date.issued2018-07-
dc.identifier.urihttp://hdl.handle.net/10144/619245-
dc.descriptionResearch Protocolen
dc.description.abstractGeneral Objectives The overall objective of this trial is to identify a safe and effective treatment for VL in HIV coinfected patients. Primary Objective: To evaluate at day 29 assessment the efficacy of a combination regimen of AmBisome® + miltefosine and AmBisome® monotherapy in Ethiopian co-infected HIV + VL patients. Secondary Objectives: 1. To evaluate relapse-free survival at day 390 (after initial cure at day 29 or cure at day 58 after extended treatment). 2. To assess safety of the regimens. Other objectives: 1.To evaluate of viral load and CD4 count in all patients 2. To evaluate the pharmacokinetics of ARV, Ambisome and miltefosine and immune function markers in a subset of patientsen
dc.language.isoenen
dc.rightsThese materials can be used, adapted and copied as long as citation of the source is given including the direct URL to the material. This work is licensed under a Creative Commons Attribution 4.0 International License: http://creativecommons.org/licenses/by/4.0/ https://i.creativecommons.org/l/by/4.0/88x31.pngen
dc.subjectAmBisome monotherapyen
dc.subjectmiltefosineen
dc.subjectVL HIV positiveen
dc.subjectThiopiaen
dc.subjectpentamidineen
dc.titleA randomized trial of AmBisome monotherapy and combination of AmBisome and miltefosine for the treatment of VL in HIV positive patients in Ethiopia followed by secondary VL prophylactic treatment with pentamidineen
dc.typeOtheren
dc.contributor.departmentMSF-OCAen
All Items in MSF are protected by copyright, with all rights reserved, unless otherwise indicated.